

ESSENTIALIS ANNOUNCES TWO PRESENTATIONS AT UPCOMING CONFERENCES

October 2, 2008 6:30 PM EDT

Carlsbad, California –(PR Newswire)- Essentialis Inc, a clinical stage pharmaceutical company, will present a company overview at the Drug Repositioning Summit at the Hyatt Harborside Hotel in Boston MA to be held on October 6th-7th 2008. The overview, entitled “Repositioning With a Twist: Establishing New Composition of Matter IP and Indications for a Marketed Drug”, will be presented on the 6th of October at 9:40 AM by Iain Dukes, President and CEO of Essentialis Inc. This will be followed by a presentation at the 16th Annual BioPartnering Europe meeting at the QEII Conference Center in London, UK on October 14th at 1:45 PM. According to Dukes “These presentations will allow us to showcase the progress the company has made to date with DCCR, our novel once-a-day lipid lowering agent which is completing an 8-week, 80 patient dose-ranging study in dyslipidemic subjects with elevated triglycerides.”

Essentialis is a pharmaceutical company based in Carlsbad, CA focused on the development of breakthrough medicines for the treatment of cardiovascular and metabolic diseases. The company's portfolio of products is targeted at the ATP-sensitive potassium channel, a metabolically-regulated membrane protein whose modulation has the potential to impact a wide range of cardiovascular and metabolic diseases. The company's lead product is in phase II studies in dyslipidemic subjects and is entering a phase I study in type I diabetes mellitus subjects.

Contacts

Neil M. Cowen

Chief Scientific Officer

nwcowen@essentialistherapeutics.com

760-431-2646.